

CLEARBRIDGE HEALTH LIMITED
(Company Registration No. 201001436C)
(the "**Company**")

COVID-19 CASES DETECTED AT MEDICAL CENTRE IN PHILIPPINES

The board of directors of Clearbridge Health Limited (the "**Company**" and together with its subsidiaries, the "**Group**") wishes to inform that Clearbridge Medical Philippines, Inc. ("**CMPI**"), a subsidiary of the Company has reported that a total of 8 people (comprising patients and staff) were tested positive for the Novel Coronavirus 2019 ("**COVID-19**") at its medical centre in Manila. They are currently being isolated and their conditions are stable.

As a precautionary measure, CMPI has voluntarily ceased the affected operations and segregated non-affected operations at the medical centre for a period of 14 days (the "**Temporary Cessation and Segregation**") with effect from today. In the meanwhile, CMPI will quarantine staff who have close contact with the infected patients and staff.

For the avoidance of doubt, the Group's other operations in the Philippines are not affected.

The Group will continue to monitor the COVID-19 situation closely and continue to practice stringent precautionary and infection control measures such as safe distancing, increased frequency of cleaning and disinfecting of premises and use of personal protective equipment to safeguard the safety and wellbeing of our patients and employees on our premises.

Revenue from the medical centre in Philippines accounted for less than 5% of the Group's revenue in FY2019, and the Temporary Cessation and Segregation is not expected to have any material impact on the financial performance of the Group for the current financial year ending 31 December 2020.

The Company will make further announcements to keep shareholders informed, as and when there are further material updates and developments to the above.

BY ORDER OF THE BOARD

Yee Pinh Jeremy
Chief Executive Officer and Executive Director

8 July 2020

*This announcement has been prepared by the Company and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "**Sponsor**"), for compliance with Rules 226(2)(b) and*

753(2) of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") Listing Manual Section B: Rules of Catalyst. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.